Data Material

Here, the efficacy and safety of ragweed SLIT-tablets during the peak and entire pollen season were evaluated in children and adolescents in a double-blind placebo-controlled clinical trial (N=1025; 77.8% polysensitized). The average total combined score (TCS; sum of rhinoconjunctivitis daily symptom score [DSS] and daily medication score [DMS]) was assessed for peak (primary endpoint) and the entire ragweed pollen season (key secondary endpoint). DSS and DMS during peak season were additional key secondary endpoints. The relative TCS improvement with ragweed SLIT-tablets versus placebo during peak season (≈186 grains/m3/day) was −38.3% and during the entire season (≈85 grains/m3/day) was −32.4%. No events of anaphylaxis, airway compromise or severe treatment-related systemic allergic reactions were reported. The authors concluded that ragweed SLIT-tablets were efficacious in children with AR/C during peak season when symptoms were greatest and throughout the entire season. To learn more about this study, watch Dr. Anne Ellis' Investigator Insights video here.